This study will evaluate the safety and immune response to GlaxoSmithKline Tdap vaccine compared to licensed Td vaccine when used as a booster in healthy adolescents (10-18 years of age).

Condition	Treatment or Intervention	Phase
Diphtheria Tetanus Pertussis	Vaccine: Combined diphtheria, tetanus, acellular pertussis vaccine	Phase III

Ages Eligible for Study:  10 Years   -   18 Years,  Genders Eligible for Study:  Both

Accepts Healthy Volunteers

Criteria

Inclusion Criteria:

• Healthy adolescents with history of completed routine vaccination against diphtheria, tetanus, and pertussis (DTP).

Exclusion Criteria:

• Use of any other investigational drug or vaccine 30 days preceding study vaccination.
• Chronic administration of immunosuppressants.
• Administration of pre-school DTP vaccine within previous 5 years.
• Administration of Td booster within previous 10 years.

Arizona
      Jonesboro,  Arizona,  72401,  United States
      Mesa,  Arizona,  85201,  United States
      Tempe,  Arizona,  85282,  United States
Arkansas
      Little Rock,  Arkansas,  72202,  United States
California
      Rolling Hills Estates,  California,  90274,  United States
      Torrance,  California,  90502,  United States
      Fountain Valley,  California,  92708,  United States
      Fullerton,  California,  92835,  United States
      Yorba Linda,  California,  92886,  United States
Colorado
      Centennial,  Colorado,  80112,  United States
      Boulder,  Colorado,  80304,  United States
      Golden,  Colorado,  80401,  United States
Connecticut
      Norwich,  Connecticut,  06360,  United States
      Middletown,  Connecticut,  06457,  United States
Florida
      Jacksonville,  Florida,  32209,  United States
      Jacksonville,  Florida,  32209,  United States
Illinois
      Chicago,  Illinois,  60614,  United States
Kentucky
      Bardstown,  Kentucky,  40004,  United States
Massachusetts
      Milford,  Massachusetts,  01757,  United States
      Woburn,  Massachusetts,  01801,  United States
      Boston,  Massachusetts,  02130,  United States
Nebraska
      Omaha,  Nebraska,  68131,  United States
New Jersey
      Whitehouse Station,  New Jersey,  08889,  United States
New York
      Stony Brook,  New York,  11794-0001,  United States
      Rochester,  New York,  14620,  United States
North Carolina
      Raleigh,  North Carolina,  27609,  United States
      Durham,  North Carolina,  27704,  United States
      Sylva,  North Carolina,  28779,  United States
Ohio
      Columbus,  Ohio,  43214,  United States
      Cleveland,  Ohio,  44109,  United States
      University Heights,  Ohio,  44118,  United States
      Akron,  Ohio,  44308-1062,  United States
Pennsylvania
      Pittsburgh,  Pennsylvania,  15241,  United States
      Sellersville,  Pennsylvania,  18960,  United States
Tennessee
      Johnson City,  Tennessee,  37615,  United States
Texas
      Temple,  Texas,  76508,  United States
      Houston,  Texas,  77030,  United States
      Bryan,  Texas,  77802,  United States
      Austin,  Texas,  78758,  United States
Utah
      West Jordan,  Utah,  84084,  United States
      Salt Lake City,  Utah,  84109,  United States
Virginia
      Norfolk,  Virginia,  23510,  United States

Study ID Numbers:  776423/001
Record last reviewed:  April 2005
Last Updated:  April 26, 2005
Record first received:  April 26, 2005
ClinicalTrials.gov Identifier:  NCT00109330
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-05-03